Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO E-Learning: Advances in Renal Cell Carcinoma Treatment

New E-Learning module by Dr Rosa Nadal and Prof Joaquim Bellmunt is now available. Watch the presentation and take the CME test today!

ESMO members

Take the CME test and receive

1 ESMO - MORA point

80 slides / 1 h 08 minutes

Learning objectives

  1. To provide an update on the current role of cytoreductive nephrectomy and metastasectomy in the management of patients with metastatic renal cell carcinoma (RCC)
  2. To provide an update on first-, second- and third-line of systemic treatment for patients with advanced RCC
  3. To provide an update on new agents and selected new combinations in the management of patients with advanced RCC
  4. To provide an update on adjuvant systemic treatment in patients with clear cell RCC

Description

In this E-Learning module, by elaborating data from clinical trials, the authors summarise evidence in terms of the current role of surgery for treatment of patients with advanced renal cell carcinoma (RCC), provide an overview of treatment landscape with first-, second-line, and beyond treatment for advanced RCC, as well as an update on adjuvant systemic treatment in patients with clear cell RCC. They also elaborate new agents, new immunotherapies and selected new combinations, thus providing an outlook for future developments in the management of patients with advanced RCC.

The authors state that cytoreductive nephrectomy should no longer be considered standard of care in intermediate- and poor-risk MSKCC groups of metastatic RCC, at least when medical treatment is required. Surgery remains an important modality, preferentially used when patients can have the majority of their disease burden resected (cytoreduction) or rendered free of macroscopic disease (metastasectomy).

In the module, the authors provide a summary of data from phase III trials on adjuvant treatment for in RCC and critically analyse the role of sunitinib or pembrolizumab for adjuvant treatment in patients with clear cell RCC who are at high risk of recurrence.

The authors state that PD-1/L1-based combination regimens with CTLA-4 inhibitors or VEGF tyrosine kinase inhibitors (TKIs) are the standard of care in first-line treatment of advanced clear cell RCC. However, there is no standard of care in the post–immuno-oncology or post-VEGF patient population, resulting in a new therapeutic challenge for clinicians. Choice of second-line systemic treatment depends on the agents(s) used in the frontline setting and use of VEGF TKIs is supported by prospective clinical data and retrospective series.

The authors state that novel agents such as HIF-2α antagonists demonstrate activity in patients pretreated with immune checkpoint inhibitors. Additional combination therapies are under investigation.

Last update: 19 Dec 2022

Joaquim Bellmunt has reported personal financial interests for Advisory Board from Astra-Zeneca, BMS, Merck, Pfizer; Invited Speaker role from Genentech, Merck, MSD; Royalties from UpToDate; institutional funding from Takeda; institutional financial interests for Coordinating PI role from MSD and Pfizer. Non-financial interests for steering committee membership from Genentech.

Rosa Nadal has no interests to declare.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.